Trial · NCT07256171
COAST Study - Cholesterol Optimization After Stroke
NCT07256171, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. COAST Study - Cholesterol Optimization After Stroke. Trials, record NCT07256171. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07256171
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- COAST Study - Cholesterol Optimization After Stroke
- NCT number
- NCT07256171
- Status
- Not yet recruiting
- Enrollment
- 500 participants, estimated
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Conditions
- Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage
- Interventions
- low-fat diet, supplements, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, or other lipid-lowering agents
- First posted
- 2025-12-01
- Last updated
- 2025-12-01
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adherence to lipid-lowering therapy | 3 months | Adherence to lipid-lowering therapy, defined as the percentage of patients who are adherent (intake of ≥80% of prescribed doses) and persistent (on therapy without interruptions) at the end of follow-up. Rates of persistence (patients who did not discontinue therapy) and adherence (patients who took it regularly) may also be considered separately. |
| Secondary | Proportion of patients achieving an LDL target value | 3 months | Proportion of patients achieving an LDL target value (for example, \<55 mg/dL for ischemic stroke patients, \<40 mg/dL for patients already on maximal therapy, etc.) at the 90 ± 15-day follow-up. This endpoint reflects the overall effectiveness of lipid-lowering management in bringing patients to the recommended target. |
| Secondary | Recurrence of stroke (ischemic or hemorrhagic), TIA, or acute cardiovascular events | 3 months | Recurrence of stroke (ischemic or hemorrhagic), TIA, or acute cardiovascular events (myocardial infarction or angina) within 90 ± 15 days of the index event (composite endpoint). The incidence of recurrent ischemic stroke, hemorrhagic stroke, and TIA will also be analyzed separately as secondary individual endpoints. |
| Secondary | All-cause mortality | 3 months | All-cause mortality at 90 ± 15 days. In parallel, cerebrovascular mortality (deaths attributable to the direct consequences of stroke or other cerebrovascular events) will be analyzed relative to mortality from other causes. |
| Secondary | Adverse events related to lipid-lowering medications | 3 months | Adverse events related to lipid-lowering medications: incidence of clinically relevant side effects reported within 90 ± 15 days (e.g., myalgias without significant CK elevation, gastrointestinal disturbances from fibrates, injection-site reactions with PCSK9 inhibitors, etc.). These will contribute to the overall evaluation of therapy tolerability. |
| Secondary | Functional disability | 3 months | Functional disability at 90 ± 15 days: optionally assessed using the mRS (modified Rankin Scale) score if captured at follow-up, to provide an overview of overall clinical outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07256171
GET https://conductscience.org/api/trials/v1/NCT07256171/registered